Devyser Diagnostics AB’s SEK 393 Million Initial Public Offering on Nasdaq Stockholm

Wigge & Partners acted as legal advisor to Carnegie. Hammarskiöld advised Devyser Diagnostics.

Carnegie Investment Bank AB (publ) (“Carnegie”) acted as Sole Global Coordinator and Sole Bookrunner in connection with the SEK 393 million initial public offering (including a fully exercised over-allotment option) of Devyser Diagnostics AB (publ)’s shares and listing on Nasdaq First North Premier Growth Market.

The prospectus in connection with the offering and listing was published on 1 December 2021 and the first day of trading in the shares on Nasdaq Stockholm was on 10 December 2021.

Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for complex DNA testing within hereditary diseases, oncology, and transplantation. The products are used to guide targeted cancer therapies, to enable a wide array of genetic tests, as well as in post-transplant follow-up. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results.

The Wigge & Partners team consisted of Peter Bäärnhielm (Picture – Partner), Emma Brolund (Senior Associate) and Carl Hedström (Associate).

Hammarskiöld’s team mainly consisted of Malin Albert (Partner), Carl-Johan Pousette (Partner), Aksel Ahlqvist (Associate) and Gustav Wahlberg (Associate).

Involved fees earner: Aksel Ahlqvist – Hammarskiöld & Co.; Malin Albert – Hammarskiöld & Co.; Carl-Johan Pousette – Hammarskiöld & Co.; Gustav Wahlberg – Hammarskiöld & Co.; Peter Bäärnhielm – Wigge & Partners; Emma Brolund – Wigge & Partners; Carl Hedström – Wigge & Partners;

Law Firms: Hammarskiöld & Co.; Wigge & Partners;

Clients: Carnegie Investment Bank AB; Devyser Diagnostic AB;

Federica Tiefenthaler

Author: Federica Tiefenthaler